Success Metrics

Clinical Success Rate
97.7%

Based on 42 completed trials

Completion Rate
98%(42/43)
Active Trials
5(8%)
Results Posted
14%(6 trials)
Terminated
1(2%)

Phase Distribution

Ph phase_2
15
24%
Ph phase_3
10
16%
Ph early_phase_1
2
3%
Ph phase_1
7
11%
Ph not_applicable
18
29%
Ph phase_4
9
14%

Phase Distribution

9

Early Stage

15

Mid Stage

19

Late Stage

Phase Distribution61 total trials
Early Phase 1First-in-human
2(3.3%)
Phase 1Safety & dosage
7(11.5%)
Phase 2Efficacy & side effects
15(24.6%)
Phase 3Large-scale testing
10(16.4%)
Phase 4Post-market surveillance
9(14.8%)
N/ANon-phased studies
18(29.5%)

Highest Phase Reached

Phase 4

Trial Status & Enrollment

Completion Rate

89.4%

42 of 47 finished

Non-Completion Rate

10.6%

5 ended early

Currently Active

5

trials recruiting

Total Trials

63

all time

Status Distribution
Active(7)
Completed(42)
Terminated(5)
Other(9)

Detailed Status

Completed42
unknown8
Withdrawn4
Recruiting3
Active, not recruiting2
Not yet recruiting2

Development Timeline

Analytics

Development Status

Total Trials
63
Active
5
Success Rate
97.7%
Most Advanced
Phase 4

Trials by Phase

Early Phase 12 (3.3%)
Phase 17 (11.5%)
Phase 215 (24.6%)
Phase 310 (16.4%)
Phase 49 (14.8%)
N/A18 (29.5%)

Trials by Status

active_not_recruiting23%
recruiting35%
not_yet_recruiting23%
completed4267%
withdrawn46%
unknown813%
suspended12%
terminated12%

Recent Activity

Clinical Trials (63)

Showing 20 of 63 trialsScroll for more
NCT07718373

Early Postoperative L-arginine and Acute Kidney Injury After Cardiac Surgery

Not Yet Recruiting
NCT03982160Phase 4

L-arginine to Reduce Sympathetic Nerve Activity in CKD Patients

Active Not Recruiting
NCT07548541Not Applicable

Acute Effects of Creatine and L-Arginine Co-Supplementation on Anaerobic and Cognitive Performance in Recreationally Active Males

Completed
NCT04800692Phase 1

The Effects of ATLAS Therapy on Nitric Oxide Bioavailability in Patients With Intermittent Claudication

Active Not Recruiting
NCT05470998Phase 3

L-Arginine in Children Having Sickle Cell Disease With Increased Tricuspid Regurgitant Jet Velocity

Completed
NCT07338682Phase 2

Evaluation of the Effect of L-Arginine on the Cognitive Function in Geriatric Patients

Recruiting
NCT07347509Not Applicable

Acute Effects of BCAA and L-Arginine on Performance in Elite Soccer Players

Completed
NCT06947265Phase 4

Safety And Efficacy Of L-Arginine Monotherapy Versus Tadalafil Monotherapy Versus Their Combination In Men With Erectile Dysfunction; A Prospective Randomized Study

Completed
NCT06475391Not Applicable

The Effects of L-arginine Supplementation on Anaerobic Exercise Performance

Recruiting
NCT03679780Phase 1

The Effect of Endothelin and L-Arginine on Racial Differences in Vasoconstriction

Completed
NCT06405477Not Applicable

EFFECTS OF L-ARGININE SUPPLEMENTATION ON THE RECOVERY OF CARDIORESPIRATORY PARAMETERS AFTER SUBMAXIMAL EXERCISE TEST

Recruiting
NCT06405243Phase 3

Myoinositol, L-arginine and Chromium With Letrozole for Ovulation Induction in Polycystic Ovarian Syndrome Patients

Not Yet Recruiting
NCT05932979Phase 2

Effect of the Administration of L-arginine vs. Placebo in Patients Diagnosed With Presbyvestibulopathy.

Withdrawn
NCT02536170Phase 2

Arginine Therapy for Sickle Cell Disease Pain

Completed
NCT03665116Not Applicable

Effects of Dietary Supplement on Osteoarthritis

Unknown
NCT01413815Not Applicable

Effect of the Amino Acid L-arginine on Perioperative Cardio-vascular Risk in Non-selected Patients

Completed
NCT04054973Phase 2

L-arginine Study for Persistent Symptoms of Schizophrenia

Withdrawn
NCT02838030Phase 2

Efficacy of Aspirin and L-arginine in High Risk Preeclamptic

Suspended
NCT04535427Phase 2

Role of L-Arginine Supplementation in the Treatment of Rheumatoid Arthritis

Unknown
NCT01841281Phase 2

L-arginine in Severe Asthma Patients Grouped by Exhaled Nitric Oxide Levels

Completed

Drug Details

Intervention Type
DRUG
Total Trials
63